Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.

Zahel T, Krysa S, Herpel E, Stenzinger A, Goeppert B, Schirmacher P, Hoffmann H, Schnabel PA, Warth A.

Virchows Arch. 2012 Mar;460(3):299-308. doi: 10.1007/s00428-012-1194-2.

PMID:
22293945
2.

Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids.

Warth A, Fink L, Fisseler-Eckhoff A, Jonigk D, Keller M, Ott G, Rieker RJ, Sinn P, Söder S, Soltermann A, Willenbrock K, Weichert W; Pulmonary Pathology Working Group of the German Society of Pathology.

Virchows Arch. 2013 May;462(5):507-13. doi: 10.1007/s00428-013-1408-2. Epub 2013 Apr 5.

PMID:
23559305
3.

Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.

Swarts DR, Rudelius M, Claessen SM, Cleutjens JP, Seidl S, Volante M, Ramaekers FC, Speel EJ.

Histopathology. 2017 Feb;70(3):412-422. doi: 10.1111/his.13096. Epub 2016 Nov 23.

PMID:
27701763
4.

Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.

Clay V, Papaxoinis G, Sanderson B, Valle JW, Howell M, Lamarca A, Krysiak P, Bishop P, Nonaka D, Mansoor W.

Clin Transl Oncol. 2017 May;19(5):579-586. doi: 10.1007/s12094-016-1568-z. Epub 2016 Nov 15.

PMID:
27848218
5.

Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.

Walts AE, Ines D, Marchevsky AM.

Mod Pathol. 2012 Sep;25(9):1258-64. doi: 10.1038/modpathol.2012.81. Epub 2012 May 11.

6.

Interobserver variability for the WHO classification of pulmonary carcinoids.

Swarts DR, van Suylen RJ, den Bakker MA, van Oosterhout MF, Thunnissen FB, Volante M, Dingemans AM, Scheltinga MR, Bootsma GP, Pouwels HM, van den Borne BE, Ramaekers FC, Speel EJ.

Am J Surg Pathol. 2014 Oct;38(10):1429-36. doi: 10.1097/PAS.0000000000000300.

PMID:
25046341
7.

Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.

Liu SZ, Staats PN, Goicochea L, Alexiev BA, Shah N, Dixon R, Burke AP.

Diagn Pathol. 2014 Oct 16;9:174. doi: 10.1186/s13000-014-0174-z.

8.

Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.

Laitinen KL, Soini Y, Mattila J, Pääkkö P.

Cancer. 2000 Apr 1;88(7):1590-8.

PMID:
10738217
9.

Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.

Kuyumcu S, Adalet I, Sanli Y, Turkmen C, Ozkan ZG, Yilmazbayhan D.

Ann Nucl Med. 2012 Nov;26(9):689-97. doi: 10.1007/s12149-012-0628-x. Epub 2012 Jul 17.

PMID:
22802007
10.

Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.

Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A.

World J Surg. 2014 Jun;38(6):1353-61. doi: 10.1007/s00268-014-2451-0.

PMID:
24493070
11.

ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.

Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A.

J Thorac Oncol. 2010 Apr;5(4):453-9. doi: 10.1097/JTO.0b013e3181ca063b.

12.
13.

Distinctive pathological and clinical features of lung carcinoids with high proliferation index.

Marchiò C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M.

Virchows Arch. 2017 Dec;471(6):713-720. doi: 10.1007/s00428-017-2177-0. Epub 2017 Jun 19.

15.

[Grading of neuroendocrine tumors].

Saeger W, Schnabel PA, Komminoth P.

Pathologe. 2016 Jul;37(4):304-13. doi: 10.1007/s00292-016-0186-4. Review. German.

PMID:
27379621
16.

Molecular markers help characterize neuroendocrine lung tumors.

Rusch VW, Klimstra DS, Venkatraman ES.

Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10.

PMID:
8784011
17.

Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.

Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, Dhall G, Colquhoun SD, Ines D, Chung F, Yu R, Nissen NN, Wolin E.

Hum Pathol. 2012 Apr;43(4):489-95. doi: 10.1016/j.humpath.2011.06.011. Epub 2011 Sep 19.

PMID:
21937080
18.

Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus.

Goto K, Kodama T, Matsuno Y, Yokose T, Asamura H, Kamiya N, Shimosato Y.

Mod Pathol. 2001 Oct;14(10):985-94.

19.

Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.

Farrell JM, Pang JC, Kim GE, Tabatabai ZL.

Cancer Cytopathol. 2014 Oct;122(10):770-8. doi: 10.1002/cncy.21457. Epub 2014 Jul 9.

20.

Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.

Rabban JT, Lerwill MF, McCluggage WG, Grenert JP, Zaloudek CJ.

Int J Gynecol Pathol. 2009 Jan;28(1):41-8. doi: 10.1097/PGP.0b013e31817a8f51.

PMID:
19047909

Supplemental Content

Support Center